MedTrace Logo

Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis

NCT02878863 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-07-13

No results posted yet for this study

Summary

An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild necroinflammatory activity on liver biopsy.

Conditions

  • Hepatitis, Autoimmune

Interventions

DRUG

Paeoniflorin + phosphatidylcholine or silymarin

DRUG

Phosphatidylcholine or silymarin

Sponsors & Collaborators

  • Xiaoli Fan

    lead OTHER

Principal Investigators

  • Li Yang, MD · West China Hospital,Chengdu, Sichuan, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-03-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02878863 on ClinicalTrials.gov